Abstract

Gene therapy has emerged as a promising approach for treating colour vision deficiencies, including red-green colour blindness. This abstract provides an overview of the advancements and challenges in gene therapy for colour vision. It highlights the genetic basis of colour blindness, the various gene therapy strategies employed, and the outcomes of preclinical and clinical studies. Ethical considerations and prospects in the field are also discussed. Gene therapy holds great potential for restoring colour vision and improving the quality of life for individuals affected by colour vision deficiencies. Further research and development in this field are crucial to overcome existing challenges and optimize the effectiveness of gene therapy interventions.